Medtronic Stock Gains Attention as Dividend Aristocrat Looks Undervalued After Strong FY2026 Results

Medtronic is drawing fresh investor interest after analysts highlighted the medical technology giant as a long-standing dividend grower trading at an attractive valuation. The discussion follows Medtronic’s latest fiscal 2026 results, where the company reported $9.8 billion in quarterly revenue, up 9.9% year over year, with organic growth of 6.6%.

The company also raised its quarterly dividend to $0.72 per share, marking its 49th consecutive year of dividend increases. That record keeps Medtronic firmly in the spotlight among income-focused investors looking for stable healthcare exposure.

Strong Earnings Support the Bullish Case

Medtronic reported non-GAAP diluted earnings per share of $1.55 for the fourth quarter of fiscal 2026, beating guidance. Full-year revenue reached $36.4 billion, rising 8.4% on a reported basis and 5.8% organically. The company said this was its strongest annual revenue growth in a decade.

A major bright spot was the cardiovascular business. Revenue in that segment reached about $3.8 billion, supported by strong demand for cardiac devices and ablation technologies. Cardiac Ablation Solutions revenue jumped 78% globally, including 124% growth in the United States.

Why Investors See Medtronic as Undervalued

The investment thesis is simple: Medtronic remains a high-quality healthcare company with steady cash flow, global scale, and a long dividend history, yet its stock has traded below some analysts’ fair value estimates. Seeking Alpha’s analysis described the stock as trading at a notable discount to estimated fair value, while also pointing to its Dividend Aristocrat profile.

For long-term investors, the appeal comes from a mix of defensive healthcare demand, dividend income, and potential recovery in valuation. Medical devices are not risk-free, but demand for heart care, surgical tools, diabetes technology, and neuroscience products tends to remain resilient across economic cycles.

Dividend Growth Remains a Key Attraction

Medtronic’s dividend increase to $0.72 per share gives the company an annualized dividend of $2.88 per share. The new dividend is payable on July 17, 2026, to shareholders of record as of June 26, 2026.

This long dividend streak is important because it shows management’s commitment to returning cash to shareholders. However, investors should still watch payout ratios, free cash flow, debt, and earnings growth to make sure future dividend increases remain sustainable.

Growth Drivers: Heart Devices, Robotics, and Innovation

Medtronic is also investing in future growth. The company has been expanding in cardiac ablation, electrophysiology, renal denervation, surgical robotics, and advanced imaging technologies. Recent investments in heart-imaging catheter companies also suggest that Medtronic wants to strengthen its cardiac care portfolio.

The Hugo robotic-assisted surgery system is another area to watch. While competition in surgical robotics is intense, Medtronic’s global hospital relationships may help it build adoption over time.

Risks Investors Should Consider

Even with a strong dividend history, Medtronic faces challenges. Its fiscal 2027 adjusted EPS outlook of $5.90 to $6.00 came in slightly below some Wall Street expectations. Tariff costs, currency movements, regulatory issues, product recalls, and competition may also pressure margins.

Another key factor is the planned separation of the diabetes business. If handled well, the move could sharpen Medtronic’s focus. But transitions can create uncertainty, and investors will want to see whether the remaining company can maintain strong growth.

Outlook

Overall, Medtronic appears to be a mature healthcare leader with improving revenue momentum, a powerful dividend record, and several innovation-driven growth opportunities. The stock may appeal to patient investors seeking income and long-term healthcare exposure, especially if they believe the current valuation does not fully reflect the company’s recovery potential.

Still, this is not a risk-free story. Investors should compare Medtronic’s valuation, growth rate, dividend safety, and competitive position before making decisions.

Sources: Medtronic investor relations, Reuters, Wall Street Journal, Barron’s, and Seeking Alpha.

#Medtronic #DividendAristocrat #HealthcareStocks #MDTStock #SlimScan #GrowthStocks #CANSLIM